首页> 外文OA文献 >Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open‐label, phase 1/2 study

【2h】

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open‐label, phase 1/2 study

机译：在复发或复发/难治多骨髓瘤（Gen 503）中的患者中，达拉姆姆人和地塞米德和地塞米松组合的疗效和耐受性：开放标签，第1/2期研究的最终结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Torben Plesner; Hendrik‐Tobias Arkenau; Francesca Gay; Monique C. Minnema; Mario Boccadoro; Philippe Moreau; Jamie Cavenagh; Aurore Perrot; Jacob P. Laubach; Jakub Krejcik; Tahamtan Ahmadi; Carla Boer; Diana Chen; Christopher Chiu; Jordan M. Schecter; Paul G. Richardson;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN GEN 503): final results of an open‐label, phase 1/2 study [J] . Plesner Torben, Arkenau Hendrik‐Tobias, Gay Francesca, British Journal of Haematology . 2019,第3期

机译：在复发或复发/难治性多发性骨髓瘤（Gen Gen 503）中的患者中，达拉姆宫和地塞米松组合的疗效和耐受性与Lenalalomide和地塞米松组合的疗效和耐受性：开放标签，第1/2期研究的最终结果
2. Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux [J] . Moreau Philippe, Kaufman Jonathan L., Sutherland Heather J., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：达那他单抗，来那度胺和地塞米松与来那度胺和地塞米松单独对先前治疗暴露量为1-3的复发或难治性多发性骨髓瘤患者的疗效：基于以前的治疗暴露：Pollux的最新分析
3. Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux [J] . Usmani Saad Z., Dimopoulos Meletios A., Belch Andrew, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：Daratumumab，来那度胺和地塞米松与来那度胺和地塞米松在复发或难治性多发性骨髓瘤患者中有1至3疗程的疗效：最新的Pollux分析
4. THALIDOMIDE PLUS INTERMEDIATE-DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED AL PATIENTS [C] . Giovanni Palladini, Vittorio PerfettF, Stefano Perlini, International Symposium on Amyloidosis . 2005

机译：沙利度胺加上难治性/复发患者中的中间剂量地塞米松
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX a randomized open-label phase 3 study [O] . Nizar J. Bahlis, Meletios A. Dimopoulos, Darrell J. White, -1

机译：Daratumumab联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤：POLLUX的扩展随访一项随机开放标签的3期研究
7. Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM) [O] . Nizar Bahlis, Meletios A Dimopoulos, Darrell J White, 2018

机译：单独的甘露三体化和地塞米松（D-Rd）与甘达胺和地塞米松（D-Rd）的3阶段跟进三年的跟踪，单独进行难倒的或难治性多发性骨髓瘤（RRMM）

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma ( GEN 503): final results of an open‐label, phase 1/2 study

著录项

相似文献

相关主题

期刊订阅